



(51) International Patent Classification:

C07D 401/04 (2006.01) *C07D 213/48* (2006.01)
C07D 401/12 (2006.01) *C07D 213/56* (2006.01)
C07D 413/04 (2006.01) *A61K 31/44* (2006.01)
C07D 213/38 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2015/046921

(22) International Filing Date:

26 August 2015 (26.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/042,717 27 August 2014 (27.08.2014) US

(71) Applicant: EPITHERAPEUTICS APS [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **BOESEN, Thomas**; Lipkesgade 25, 2.tv, DK-Ø 2100 København (DK). **LABELLE, Marc**; 10 Melbourne Way, Basking Ridge, New Jersey 07920 (US). **YANG, Ying**; 4001 Nicolet Ave, Apt. 14, Fremont, California 94536 (US). **SARASWAT, Neerja**; 47 Smuggler's Cove, Winnipeg, Manitoba R3X 1R4 (CA). **DUDEKULA, Dastagiri**; 208-1055 Grant Avenue, Winnipeg, Manitoba R3M 1Y5 (CA). **COOK, Cyril John**; 9-675 Thibault Street, Winnipeg, Manitoba R2H 3B2 (CA). **VAKITI, Ramkrishna Reddy**; 1281 Grant Avenue, # 312, Winnipeg, Manitoba R3M 1Z6 (CA). **ZHANG, Rui**; 71 Briar Cliff Bay, Winnipeg, Manitoba R3T 3H8 (CA). **ULLAH, Farman**; 604-1305 Taylor Avenue, Winnipeg, Manitoba R3M 2K6 (CA).

(74) Agents: **ERLACHER, Heidi A.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES



(57) Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIia), (IIb), (IIc), (Hid), (Hie), (IIIf), and (IIlg). Compounds of Formula (I) have the structure: wherein Q, R¹, R¹⁸, R¹⁹, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.